A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma-Reference-Cited by-同舟云学术

A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma

Published:2021 Issue:3 Volume:61 Page:162-167
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Ohnishi Kazunori¹,Ohmachi Ken²,Ando Kiyoshi²,Yamamoto Kazuhito³,Ito Tatsuya⁴,Tanimoto Mitsune⁵,Ohbayashi Kaneyuki⁶,Ohyashiki Kazuma⁷,Tsukasaki Kunihiro⁸,Naito Kensuke⁹,Suzuki Takayo¹⁰,Ono Takaaki¹,Miyamura Koichi¹¹,Kagami Yoshitoyo¹²,Kinoshita Tomohiro³,Hotta Tomomitsu¹³,Ogura Michinori¹⁴

Affiliation:

1. Department of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan,

2. Department of Hematology and Oncology, Tokai University, Isehara, Japan,

3. Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan,

4. Department of Hematology, Anjo Kosei Hospital, Anjo, Japan,

5. Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan,

6. Department of Hematology, Toyota Memorial Hospital, Toyota, Japan,

7. Department of Hematology, Tokyo Medical University, Tokyo, Japan,

8. Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan,

9. Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan,

10. Department of Hematology, Shiga General Hospital, Moriyama, Japan,

11. Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan,

12. Department of Hematology, Toyota Kosei Hospital, Toyota, Japan,

13. National Hospital Organization Nagoya Medical Center, Nagoya, Japan,

14. Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/61/3/61_21004/_pdf

Reference20 articles.

1. 1 Chihara D, Ito H, Matsuda T et al. Differences in incidence and trends of haematological malignancies in J apan and the United States. Br J Haematol. 2014; 164: 536-545.

2. 2 Leonard JP, Nastoupil LJ, Flowers CR. Where to start? Upfront therapy for follicular lymphoma in 2018. Hematology (Am Soc Hematol Educ Program). 2018; 2018: 185-188.

3. 3 Luminari S, Ferrari A, Manni M et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018; 36: 689-696.

4. 4 Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381: 1203-1210.

5. 5 Flinn IW, van der Jagt R, Kahl B et al. First-Line Treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell Lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019; 37: 984-991.